XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Revision of Prior Period, Accounting Standards Update, Adjustment [Member]
Accumulated Deficit [Member]
Revision of Prior Period, Accounting Standards Update, Adjustment [Member]
Total
Balance (Accounting Standards Update, Topic 326 [Member]) at Dec. 31, 2019       $ (32)   $ (32)  
Balance at Dec. 31, 2019 $ 153 $ 1,120,999 $ 5   $ (1,066,240)   $ 54,917
Balance, shares at Dec. 31, 2019 153,119            
Net Income loss         (45,532)   (45,532)
Other comprehensive income loss     113       113
Issuance of common stock in conjunction with equity plans $ 4 14,170         14,174
Issuance of common stock in conjunction with equity plans, shares 4,473            
Issuance of common stock from underwritten public equity offering, net of issuance costs $ 23 93,575         93,598
Issuance of common stock from underwritten public equity offering, net of issuance costs, shares 22,345            
Stock-based compensation expense   12,258         12,258
Balance at Sep. 30, 2020 $ 180 1,241,002 118   (1,111,804)   129,496
Balance, shares at Sep. 30, 2020 179,937            
Balance at Jun. 30, 2020 $ 154 1,129,091 243   (1,088,096)   41,392
Balance, shares at Jun. 30, 2020 154,318            
Net Income loss         (23,708)   (23,708)
Other comprehensive income loss     (125)       (125)
Issuance of common stock in conjunction with equity plans $ 3 13,344         13,347
Issuance of common stock in conjunction with equity plans, shares 3,274            
Issuance of common stock from underwritten public equity offering, net of issuance costs $ 23 93,575         93,598
Issuance of common stock from underwritten public equity offering, net of issuance costs, shares 22,345            
Stock-based compensation expense   4,992         4,992
Balance at Sep. 30, 2020 $ 180 1,241,002 118   (1,111,804)   129,496
Balance, shares at Sep. 30, 2020 179,937            
Balance at Dec. 31, 2020 $ 192 1,372,083 85   (1,036,869)   $ 335,491
Balance, shares at Dec. 31, 2020 192,294           192,294
Net Income loss         (111,894)   $ (111,894)
Other comprehensive income loss     (58)       (58)
Issuance of common stock in conjunction with equity plans $ 9 30,113         30,122
Issuance of common stock in conjunction with equity plans, shares 8,126            
Issuance of common stock in Private Placement, net of issuance costs $ 11 294,834         294,845
Issuance of common stock in Private Placement, net of issuance costs shares 11,215            
Issuance of common stock in acquisition of Omniome $ 9 237,875         237,884
Issuance of common stock in acquisition of Omniome, shares 8,912            
Stock-based compensation expense   54,417         54,417
Balance at Sep. 30, 2021 $ 221 1,989,322 27   (1,148,763)   $ 840,807
Balance, shares at Sep. 30, 2021 220,547           220,547
Balance at Jun. 30, 2021 $ 199 1,423,357 (6)   (1,165,305)   $ 258,245
Balance, shares at Jun. 30, 2021 198,917            
Net Income loss         16,542   16,542
Other comprehensive income loss     33       33
Issuance of common stock in conjunction with equity plans $ 2 4,809         4,811
Issuance of common stock in conjunction with equity plans, shares 1,503            
Issuance of common stock in Private Placement, net of issuance costs $ 11 294,834         294,845
Issuance of common stock in Private Placement, net of issuance costs shares 11,215            
Issuance of common stock in acquisition of Omniome $ 9 237,875         237,884
Issuance of common stock in acquisition of Omniome, shares 8,912            
Stock-based compensation expense   28,447         28,447
Balance at Sep. 30, 2021 $ 221 $ 1,989,322 $ 27   $ (1,148,763)   $ 840,807
Balance, shares at Sep. 30, 2021 220,547           220,547